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Homocysteine-lowering therapy combined with the standard therapy of patients 
with CHD with В12 deficiency is clinically more effective and more cost effective 
compared to the standard therapy.
PCV173
Are SPAniSh regionS imPlementing the nAtionAl therAPeutiC 
PoSitioning rePort (tPr) regArding new orAl AntiCoAgulAntS (noAC) 
in the SAme wAy? A CASe of regionAl VAriAbility in drug ACCeSS
Rodriguez Barrios JM1, Pérez-Alcántara F2, Gonzalez-Juantey JR3, Avendaño C4, Suarez C5, 
López-Bastida J6, Barja de Soroa P1
1Daiichi-Sankyo, Madrid, Spain, 2OBLIKUE Consulting, Barcelona, Spain, 3Santiago University 
Hospital, Santiago de Compotela, Spain, 4Puerta de Hierro University Hospital, Madrid, Spain, 
5La Princesa University Hospital, Madrid, Spain, 6Castilla La Mancha University, Talavera de la 
Reina, Spain
Objectives: As Other EU countries Spain is a decentralized health care system, 
and some measurements were implemented to ensure equity in the system. The 
Therapeutic Positioning Report is a new procedure set up by the Spanish Agency of 
Medicines (AEMPS) and the Ministry of Health in May 2013 as part of the National 
pricing and reimbursement process for new drugs; Its aim was to reduce market 
access timelines and ensure a nation-wide implementation of reimbursement cri-
teria, regional governments participated in this initiative. Our aim was to evaluate 
the implementation of this procedure inside the NOAC drug class. MethOds: We 
developed a structured search by collecting the official reports from the TPR at the 
AEMPS, and the different applications of the NOACs used in Non-Valvular Atrial 
Fibrillation (NVAF) among the 17 Regional Health Systems. These applications were 
evaluated through the different visa inspection procedures that regional govern-
ments use to approve NOAC prescriptions. We summarized this information and fed 
a data collection sheet developed ad hoc to show the differences between regions 
and compared with the National TPR. We evaluated 8 different criteria included in 
the National TPR for NOAC. Results: We found regional differences among the 8 
criteria identified in the NOAC TPR. Main differences were found in key aspects from 
patient access perspective i.e.: different clinical criteria for NOAC indication, allow-
ance of prescription by GPs, INR control criteria to switch from traditional antico-
agulants to NOAC, etc. Three different groups of regions were identified attending to 
the number of criteria coinciding with the TPR. cOnclusiOns: There are different 
patterns of implementation of the TPR at regional level in Spain, leading to different 
access barriers that translate into patient inequities of access and differences in 
NOAC prescription by region.
PCV174
relAtionShiP between AdherenCe to PoSt PerCutAneouS CoronAry 
interVention (PCi) guidelineS And CliniCAl outComeS of PoSt-PCi 
PAtientS in hong Kong - A 5-yeAr retroSPeCtiVe Cohort Study
Hui KC1, Tang SC1, Yan BP2, Lee VW1
1The Chinese University of Hong Kong, Shatin, Hong Kong, 2Chinese University of Hong Kong, 
Shatin, Hong Kong
Objectives: This study aimed to investigate the relationship between post-PCI 
guideline adherence and 5- year clinical outcomes of post-PCI patients in Hong 
Kong. MethOds: Retrospective data and information was retrieved from the PCI 
registry and electronic patient record system in Prince of Wales Hospital, Hospital 
Authority. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention 
was chosen as reference for post-PCI recommended therapies. Total five post-PCI 
guideline-recommended therapies were included in analysis for the relationship 
with 5-year clinical outcomes, the major adverse cardiac events (MACE). Results: 
Total 276 (68.3%) PCI patients completed 5-year follow-up. Forty-four (15.9%) patients 
experienced MACE in the 5-year period with 23 (52.3%) as cardiac death, 11 (25%) 
as non-fatal myocardial infraction, and 10 (22.7%) as target vascular revasculari-
zation. Only 40 (14.5%) patients fully adhered to all five guideline-recommended 
therapies with a mean total percentage adherence of 77.8%. Diabetes management 
(95.2%) was the most adherent therapy and lipid management was the least adher-
ent therapy (40.7%). Only 64.73% of patients adhered to dual antiplatelet therapy 
with 89.9% and 71.0% of patients adhered to aspirin and clopidogrel respectively. 
Five-year total percentage adherence and dual antiplatelet therapy adherence did 
not significantly correlate with the 5-year clinical outcomes in post-PCI patients. 
However, one of the guideline-recommended therapies, the adherence to aspirin 
was significantly associated with reduced 5-year rates of MACE (adjusted OR 0.071, 
95% CI 0.005-0.981, p = 0.048) and cardiac deaths (adjusted OR 0.036, 95% CI 0.002-
0.742, p = 0.031). The adherence of dual antiplatelet therapy and lipid management 
were significant associated with reduced non-cardiac deaths (adjusted OR 0.224, 
95% CI 0.072-0.700, p = 0.031) and numbers of hospital admissions (adjusted beta 
-0.135, 95% CI -1.126 to -0.035, p = 0.037) respectively. cOnclusiOns: Adherence 
to aspirin, dual antiplatelet therapy, and lipid management were associated with 
better 5-year clinical outcomes in post-PCI patients.
PCV175
A mAnAgement View on heAlth eConomiCS - CASe Study on networK 
metA AnAlySeS (nmA) for PulmonAry ArteriAl hyPertenSion (PAh)
Daneasa D, Migliore A, Jegers M
Vrije Universiteit Brussel, Brussels, Belgium
Objectives: Demonstrate the need for re-opening the debate around the differ-
ent treatment guidelines for Pulmonary Arterial Hypertension (PAH) by asking the 
question: How much money could the UK NHS potentially save if they had a clear a 
ranking of the different oral PAH treatments, based on their clinical effectiveness / 
ICER ratio? Currently the clinical effect ranking of the standard treatments does not 
exist; there only exists a ranking of costs related to each health technology. Once the 
clinical effect ranking is established, the intention of this paper is to investigate how 
this ranking matches/correlates with the ranking of costs and then assess it’s likeky 
impact on the NHS spending, with the intention of making it more efficient - start-
ing from the hypothesis that the current treatment guidelines will be followed for 
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Objectives: the objective of the project is to evaluate the impact of health care 
resources and the related health care costs in relation to outcomes occurred in 10 
years on the cohort of 2002 and intervention on secondary prevention cohort 2010 
with a follow-up to 3 years. MethOds: from 2000 and 2012, Local HealthCare Unit 
(ASLn°1) of Milan identified a cohort of 26.062 patients with RCV (Cardiovascular 
risk). Data analysis was done trough a retrospective claims data study from ASLn°1 
of Milan; Physicians who participated were 494. Information has been collected 
for inclusion in the study regarding some risk factors and treatment. At the end of 
2012 reduced the effects of smoking and BMI after ad hoc training events for physi-
cians. Results: 12,000 subjects were recruited and followed for 3 years with reduc-
tion of spending on the NHS system and reduced incidence of events. A resources 
utilization analysis has been developed using profiles of treatments and dividing 
the population into groups with homogeneous treatment (smoking and BMI control 
vs. standard care), verifying the occurrence of greater outcomes and related health 
care costs. Data are analyzed with the definition of major cardiovascular events, 
all-cause mortality and cause-specific, occurrence of diabetes and other chronic 
greater diseases, verifying the occurrence of greater outcomes and related health 
care costs. 60% of population were > 65 years, 63% were males. Average for paper of 
the risk is 3 for patients over 65 years. The average score is different between males 
and females (4 males and 2 females). cOnclusiOns: administrative databases 
offer low-cost information (since they are already available) regarding more or less 
all services provided in a healthcare environment. These sources and their integra-
tion are a powerful tool supporting conventional methods used in epidemiological 
studies and as tools for plan Healthcare policy.
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Objectives: Heart failure (HF) is a major reason for hospital admissions (HA), with 
a high socio-economic impact. Therefore it is of utmost importance to understand 
how HA due to HF are evolving. This study aimed to build a predictive model for 
the annual number of HA due to HF in Portugal. MethOds: Hospital admissions 
due to HF, between 2003 and 2012, were extracted from National Diagnosis-related 
group database. Demographic and socioeconomic data were collected per district, 
from Statistics Portugal. Generalized linear mixed-effects models (GLMM) were 
used to estimate the annual number of HA. Spatial heterogeneity was corrected 
by considering region-related independent variables (IV): proportion of population 
aged ≥ 65, average monthly income and hospital access. Random effects were con-
sidered for all IV. Results: The fixed effect estimates indicate that, in average, the 
number of HA due to HF increase by 12.4% per year. An increase of 1% in the pro-
portion of population aged ≥ 65 accounts for an increase of 3% in HA. The increase 
of 100€ in the monthly income represents an average decrease of 22.5% in HA. By 
its turn, 1 more hospital per 100,000 inhabitants accounts for an increase of 5.3% 
in HA. These changes are conditional to all the other IV remaining unchanged. 
Estimated random effects accounted for spatial heterogeneity by introducing cor-
rections around the fixed effects. The fitted model was compared to a GLMM without 
random effects for the region-related IV and a fixed effects model. Mean absolute 
deviations (MAD), used to assess goodness of fit, were 34.8, 56.4 and 131, respectively. 
Graphical representation also demonstrated that our model fitted better. Predictive 
ability of the model was assessed by MAD of forecast for 2012 based on 2003-2011 
data (MAD= 77.2). cOnclusiOns: Although this approach produced good results, 
the predictive ability could be further improved by the inclusion of other region-
related variables.
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Objectives: Reasonability of vitamins В6, В12and folic acid (FA) for the preven-
tion of cardiovascular complications in patients with coronary heart disease (CHD) 
is debated. The aim of the study is to assess the cost effectiveness of homocyst-
eine-lowering and standard therapy versus standard therapy in patients with 
CHD. MethOds: Results of the clinical randomized trial [O. O. Shakhmatova, A. 
Komarov, A. N. Samko et al. / Rational Pharmacotherapy in Cardiology, 2011; 7(2), 524-
35]. Cost-effectiveness analysis of homocysteine-lowering therapy by vitamins В6, 
В12and FA combined with the standard therapy versus the standard therapy (anti-
platelet, statin, antihypertensive drugs: ACE inhibitors, beta-blockers) in patients 
with CHD and postPCI, with the elevated level of homocysteine affected by cyano-
cobalamin deficiency. The first level of costs, i.e. the cost of treatment, was taken 
into account. Results: Two treatment regimens were analyzed: the first regimen 
“vitamins + standard”: patients (n= 97) of which since the randomization received 
FA (0.6 mg/day), vitamin В6 (4 mg/day) and vitamin В12 (10 µg/day) along with the 
standard treatment. Patients in the control group (n= 167) received only standard 
therapy. The observation period was 20 months. The first regimen “vitamins + stand-
ard” contributed to reduction of the total combined outcome: cardiovascular death, 
acute coronary syndrome, stroke, revascularization by 95.0%, standard therapy – by 
65.7%. The costs amounted to € 371 for the regimen “vitamins + standard” and € 271 
for the standard therapy, respectively. The “cost-effectiveness” ratio have showed 
that the treatment regimen “vitamins + standard” is more cost effective, its use 
compared to the standard therapy requires additional expenses in the amount of 
€ 307.17 for 1 additional prevented event that did not occurred. cOnclusiOns: 
